ARDS — Aridis Pharmaceuticals, Inc.
$0.00
+$0.00 (+0.00%)
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S.
Market Cap
$4457.00
Forward P/E
-0.0x
52-Week Range
N/A
ARDS Price History
Revenue vs. Net Income
$3.1M
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$29.2M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.4x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2.7%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+52.8%
Dilution · FY2022
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
